Pharma Risk-Sharing Agreement Services

Although uncertainty over clinical outcomes should be priced into new drugs, the real world performance of the drug after approval often remains unclear, and payors often demand risk-sharing arrangements. Our Pharma Risk-Sharing Agreement Services provide critical intelligence on the rising risk-sharing phenomenon in pricing and reimbursement strategies.

Subscribers to this service  can chose one or more of the three deliverables we offer to help them weigh a risk-sharing arrangement:

• Risk-Sharing Database: a continually, updated online system for comparing and evaluating agreements across therapeutic areas, drugs, and geographies 
• Risk-Sharing Agreements: original cross-country research on market and regulatory risk-sharing trends and developments based on primary research through interviews with payors, pharmacists and KOLs. 
• Risk-Sharing Quarterly Analysis: a PowerPoint presentation that shows the strengths and weaknesses of current areements and updates new trends and arrangements, providing unparalleled insight into the success or failure of previous risk-sharing agreements

Benefits:

Pharma Risk-Sharing Agreement Services enables you to:

• Determine whether to enter into a risk-sharing agreement 
• Stay abreast of regulatory and market risk-sharing trends and developments 
• Ealuate and learn from the successes and failures of current risk-sharing agreements

Risk-Sharing Database

• Continually updated online service that compares and contrasts agreements across all therapeutic areas, drugs, and geographies

Risk-Sharing Agreements: An Alternative Approach to Pricing Negotiations

• A multi-client study delivering unique, in-depth analysis based on primary research with payors and key opinion leaders 
• Cross-country comparisons of regulatory and market trends for risk-sharing agreements

Risk-Sharing Quarterly Analysis 

• A quarterly PowerPoint that monitors new agreements and developments, including key themes such as: 
  Transparency 
• Risk sharing in emerging markets 
• Agreements that fail to secure reimbursement

Our expert team provides an independent, fact-based view of the healthcare and pharmaceutical industry, fully supported by our 325+ economists and analysts worldwide with expertise in over 120 industries and 200 countries.

IHS Global Insight is the world leader in economic and financial analysis, forecasting, and market intelligence—with more than 40 years experience and an outstanding record for accuracy.